Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Korzenik JR.

Dig Dis Sci. 2012 Feb;57(2):472-80. doi: 10.1007/s10620-011-1896-3. Epub 2011 Sep 11.

PMID:
21909990
2.
3.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Smith LS, Nelson M, Dolder CR.

Ann Pharmacother. 2010 Feb;44(2):333-42. doi: 10.1345/aph.1M314. Epub 2010 Jan 5. Review.

PMID:
20118143
4.

Certolizumab pegol in the treatment of Crohn's disease.

Ferrante M, Vermeire S, Rutgeerts P.

Expert Opin Biol Ther. 2013 Apr;13(4):595-605. doi: 10.1517/14712598.2013.777039. Epub 2013 Mar 4. Review.

PMID:
23451881
5.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127.

PMID:
20014021
6.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
7.

Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.

Augustine JM, Lee JK, Armstrong EP.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680. Review.

PMID:
25209304
8.

Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.

Tun GS, Lobo AJ.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):317-27. doi: 10.1517/17425255.2015.995166. Review.

PMID:
25586216
9.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

10.

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Gisbert JP, Marín AC, McNicholl AG, Chaparro M.

Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Review.

11.

Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.

Tang DH, Armstrong EP, Lee JK.

Pharmacotherapy. 2012 Jun;32(6):515-26. doi: 10.1002/j.1875-9114.2011.01053.x. Epub 2012 Apr 23.

PMID:
22528603
12.

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.

Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK.

Aliment Pharmacol Ther. 2014 Jun;39(12):1349-62. doi: 10.1111/apt.12749. Epub 2014 Apr 20. Review.

13.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
14.

Drug safety evaluation of certolizumab pegol.

Ferrante M, Vermeire S, Rutgeerts PJ.

Expert Opin Drug Saf. 2014 Feb;13(2):255-66. doi: 10.1517/14740338.2014.851666. Epub 2013 Oct 25. Review.

PMID:
24156537
15.

A review and expert opinion of the use of certolizumab for Crohn's disease.

Evans AT, Lee SD.

Expert Opin Biol Ther. 2012 Mar;12(3):363-70. doi: 10.1517/14712598.2012.658770. Review.

PMID:
22339409
16.

Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R.

Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. Review.

17.

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

Patil SA, Rustgi A, Langenberg P, Cross RK.

Dig Dis Sci. 2013 Jan;58(1):209-15. doi: 10.1007/s10620-012-2323-0. Epub 2012 Sep 27.

PMID:
23014844
18.

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):423-31.e1. doi: 10.1016/j.cgh.2013.10.025. Epub 2013 Nov 1.

PMID:
24184736
19.

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357.

20.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.

Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Review. Erratum in: Am J Gastroenterol. 2011 Feb;106(2):375. Watermayer, G [corrected to Watermeyer, G].

PMID:
21045814

Supplemental Content

Support Center